How should I transition a patient from Vyvanse (lisdexamfetamine) to Jornay PM (methylphenidate extended‑release), including starting dose, titration schedule, and monitoring?

Switching from Vyvanse to Jornay PM

Discontinue Vyvanse and start Jornay PM at 20 mg taken in the evening (8:00 PM), then titrate weekly by 20 mg increments based on response and tolerability—do not convert on a milligram-per-milligram basis. 1

Key Transition Principles

The FDA label for Jornay PM explicitly states that when switching from other methylphenidate products (and by extension, other stimulants like lisdexamfetamine), you should discontinue the prior treatment and titrate Jornay PM using the standard titration schedule rather than attempting dose equivalency 1. This is critical because:

• Jornay PM has a unique delayed-release/extended-release pharmacokinetic profile that differs fundamentally from Vyvanse (an amphetamine prodrug)
• The medications have different methylphenidate base compositions and release mechanisms 1
• Cross-class stimulant conversions (amphetamine to methylphenidate) lack validated conversion ratios

Specific Transition Protocol

Step 1: Discontinue Vyvanse

• Stop Vyvanse on the day before starting Jornay PM
• No washout period is required when switching between stimulant classes
• Ensure patient is not on MAO inhibitors (14-day contraindication) 1

Step 2: Starting Dose

• Begin with 20 mg Jornay PM taken at 8:00 PM regardless of prior Vyvanse dose 1
• This evening dosing provides symptom control the following morning and throughout the day
• Take consistently with or without food (choose one method and maintain it)

Step 3: Titration Schedule

• Titrate weekly in 20 mg increments based on efficacy and tolerability 1
• Available doses: 20,40,60,80,100 mg
• Maximum studied dose is 100 mg daily (do not exceed) 1
• Adjust timing between 6:30 PM and 9:30 PM to optimize next-day symptom control 1

Step 4: Monitoring During Transition

Early monitoring is essential because adverse events occur frequently during initial dosing:

• 52% of adverse events occur within the first 30 days 2
• 54% of adverse events occur at lower doses (20-40 mg) 2

Monitor specifically for:

• Decreased appetite (most common, 62.4% with methylphenidate products) 3
• Insomnia (28.7%) 3
• Irritability/aggression (26.1%) 3
• Weight loss (21.1%) 3
• Cardiovascular parameters (blood pressure, heart rate) 1

Critical Clinical Considerations

Why Not Direct Conversion?

Research shows that 41% of patients require switching between stimulant families (methylphenidate vs. amphetamine) due to poor tolerability 4. This high switching rate underscores that response is highly individual and cannot be predicted by baseline characteristics. The pharmacokinetic profiles are too different to allow direct conversion 1.

Managing Adverse Events

Do not immediately discontinue if adverse events emerge—this is a key learning from clinical trials versus real-world practice 2. In postmarketing surveillance, clinicians frequently discontinued treatment after adverse events, whereas trial investigators continued optimization and found most adverse events became tolerable with dose adjustment or time 2.

Instead:

• Reduce dose if adverse events are significant
• Adjust timing of administration (within 6:30-9:30 PM window)
• Allow time for tolerance to develop to common effects like appetite suppression
• Only discontinue if adverse events persist despite dose reduction 1

Expected Timeline

• Week 1-4: Titration phase with weekly dose adjustments
• By 1 month: Most patients reach optimal dose
• If no improvement after appropriate dosage adjustment over one month, discontinue Jornay PM 1

Special Populations

• Not recommended for children under 6 years due to higher plasma exposure and adverse event rates 1
• Pre-treatment cardiac screening is mandatory (personal/family history of sudden death, arrhythmia, structural heart disease) 1
• Screen for tics or Tourette's syndrome before initiating 1

Common Pitfalls to Avoid

1. Attempting dose equivalency: There is no validated conversion ratio between lisdexamfetamine and methylphenidate—always start at 20 mg 1

2. Morning dosing: Jornay PM must be taken in the evening; morning administration negates its delayed-release design 1

3. Premature discontinuation: Many adverse events resolve with continued treatment or dose adjustment 2

4. Inadequate titration time: Allow at least one week between dose increases to assess response 1

5. Splitting capsules: The entire capsule contents must be taken at once (can sprinkle on applesauce but consume immediately without chewing) 1